- Home
- FTS vs ONC Comparison
FTS vs ONC Comparison
Compare FTS & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTS
- ONC
- Stock Information
- Founded
- FTS 1885
- ONC 2010
- Country
- FTS Canada
- ONC Switzerland
- Employees
- FTS N/A
- ONC N/A
- Industry
- FTS Electric Utilities: Central
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- FTS Utilities
- ONC Health Care
- Exchange
- FTS Nasdaq
- ONC Nasdaq
- Market Cap
- FTS 24.6B
- ONC 26.9B
- IPO Year
- FTS N/A
- ONC N/A
- Fundamental
- Price
- FTS $48.84
- ONC $245.58
- Analyst Decision
- FTS Hold
- ONC Strong Buy
- Analyst Count
- FTS 1
- ONC 7
- Target Price
- FTS $72.00
- ONC $326.43
- AVG Volume (30 Days)
- FTS 617.5K
- ONC 368.4K
- Earning Date
- FTS 05-07-2025
- ONC 05-07-2025
- Dividend Yield
- FTS 3.52%
- ONC N/A
- EPS Growth
- FTS 5.83
- ONC N/A
- EPS
- FTS 2.30
- ONC N/A
- Revenue
- FTS $8,159,460,114.00
- ONC $4,180,740,829.00
- Revenue This Year
- FTS $10.96
- ONC $32.78
- Revenue Next Year
- FTS $4.24
- ONC $19.07
- P/E Ratio
- FTS $21.35
- ONC N/A
- Revenue Growth
- FTS 3.64
- ONC 52.09
- 52 Week Low
- FTS $38.15
- ONC $141.31
- 52 Week High
- FTS $50.06
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- FTS 58.40
- ONC N/A
- Support Level
- FTS $45.87
- ONC N/A
- Resistance Level
- FTS $48.92
- ONC N/A
- Average True Range (ATR)
- FTS 0.73
- ONC 0.00
- MACD
- FTS 0.03
- ONC 0.00
- Stochastic Oscillator
- FTS 94.59
- ONC 0.00
About FTS Fortis Inc.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving more than 3.4 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.